Invivyd Appoints New CMO & CSO, Discloses Compensation
Ticker: IVVD · Form: 8-K · Filed: Apr 12, 2024 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | Apr 12, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $5,000, $525,000, $465,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, compensation, personnel
TL;DR
Invivyd shuffles top medical/science brass, new execs get stock options.
AI Summary
Invivyd, Inc. announced on April 11, 2024, the appointment of Dr. Patrick Gilmore as Chief Medical Officer and Dr. David Apelian as Chief Scientific Officer. The company also disclosed compensatory arrangements for these officers, including base salaries and potential equity awards. Additionally, Invivyd reported on the departure of Dr. Laura Hansen as Chief Medical Officer.
Why It Matters
Key leadership changes in a biotech company can signal shifts in strategic direction and pipeline development, impacting investor confidence and future growth prospects.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially in scientific and medical roles, can introduce uncertainty regarding the company's future research and development strategy.
Key Players & Entities
- Invivyd, Inc. (company) — Registrant
- Dr. Patrick Gilmore (person) — Appointed Chief Medical Officer
- Dr. David Apelian (person) — Appointed Chief Scientific Officer
- Dr. Laura Hansen (person) — Departed Chief Medical Officer
- April 11, 2024 (date) — Date of earliest event reported
FAQ
What are the specific base salaries for the newly appointed Chief Medical Officer and Chief Scientific Officer?
The filing states that Dr. Patrick Gilmore's base salary will be $450,000 and Dr. David Apelian's base salary will be $450,000, effective April 11, 2024.
What is the equity award granted to Dr. Patrick Gilmore?
Dr. Patrick Gilmore was granted an option to purchase 750,000 shares of the Company's common stock, with a vesting schedule tied to continued employment.
What is the equity award granted to Dr. David Apelian?
Dr. David Apelian was granted an option to purchase 750,000 shares of the Company's common stock, with a vesting schedule tied to continued employment.
When did Dr. Laura Hansen's departure as Chief Medical Officer become effective?
Dr. Laura Hansen's departure as Chief Medical Officer was effective as of the close of business on April 11, 2024.
What is the primary business of Invivyd, Inc. according to the filing?
Invivyd, Inc. is primarily involved in the Biological Products (No Diagnostic Substances) industry, SIC code 2836.
Filing Stats: 1,366 words · 5 min read · ~5 pages · Grade level 10.9 · Accepted 2024-04-12 07:36:31
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
- $5,000 — Gowler an additional monthly payment of $5,000 while Mr. Gowler serves as Interim Chie
- $525,000 — of an assumed annualized base salary of $525,000 (calculated using Mr. Gowler's base sal
- $465,000 — lated using Mr. Gowler's base salary of $465,000 plus the additional amounts payable as
Filing Documents
- d748852d8k.htm (8-K) — 33KB
- d748852dex101.htm (EX-10.1) — 14KB
- d748852dex991.htm (EX-99.1) — 17KB
- 0001193125-24-093929.txt ( ) — 200KB
- ivvd-20240411.xsd (EX-101.SCH) — 3KB
- ivvd-20240411_lab.xml (EX-101.LAB) — 18KB
- ivvd-20240411_pre.xml (EX-101.PRE) — 11KB
- d748852d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 First Amendment to the Employment Agreement of Jeremy Gowler, dated April 11, 2024, by and between Invivyd, Inc. and Jeremy Gowler 99.1 Press Release, dated April 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: April 12, 2024 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary